
On 12 July news broke that Novartis, Amgen and Banner’s Alzheimer’s Institute were discontinuing a trial into investigational compound CNP520 …

Boehringer Ingelheim has bought Swiss biotech AMAL Therapeutics, a company focused on cancer immunotherapy and cancer vaccines. AMAL’s lead candidate, …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

